Evaluation of Oxidant-Antioxidant Status of Fluvoxamine on Human Lymphocyte Cell Culture

Abstract

Depression is one of the prevalent psychiatric diseases in Turkey and the world. Fluvoxamine is a strong selective serotonin reuptake inhibitor (SSRI) that is used as an antidepressant. No study investigating the doses of Fluvoxamine treatment that may lead to a disruption in the oxidant-antioxidant balance on the cellular level in addition to its beneficial effects has been found in the literature. For this purpose, by creating Fluvoxamine application groups at the doses of 7.5, 15, 30 and 60 μM and durations of 24 and 48 hours on human lymphocyte cell cultures, we investigated the total oxidant status (TOS), total antioxidant status (TAS) and oxidative stress index (OSI). According to the results of the study, the TOS levels of all dose groups increased significantly in the 24- and 48-hour applications (p<0.05). While the TAS levels significantly increased in the 24-hour application of the doses of 7.5 and 15 μM and 48-application of the dose of 7.5 μM, they significantly decreased in the 24- and 48-hour applications of the doses of 30 and 60 μM (p<0.05). The OSI level increased significantly in the 24- and 48-hour applications of the doses of 30 and 60 μM. The results of our study demonstrated that, in the 24- and 48-hour applications of the doses of 30 and 60 μM, the antioxidant system could not compensate and the cells exposed to oxidative stress.

Keywords

• Human lymphocyte cell culture
• Total oxidant status (TOS)
• Total antioxidant status (TAS)
• Oxidative stress index (OSI)
• Fluvoxamine

References

1. Möller HJ, Bitter I, Bobes J, Fountoulakis K, Höschl C, Kasper S. European Psychiatric Association. Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. European Psychiatry 27(2) (2012) 114-128.
2. Gadassi R, Mor N. Confusing acceptance and mere politeness: Depression and sensitivity to Duchenne smiles. Journal of Behavior Therapy and Experimental Psychiatry 50 (2016) 8-14.
3. Açıkgöz A, Dayı A, Binbay T. Üniversitede okuyan kız öğrencilerde depresyon prevalansı ve ilişkili faktörler. Cukurova Medicine Journal 43(1) (2018) 131-140.
4. Semenkovich K, Brown ME, Svrakic DM, Lustman PJ. Depression in type 2 diabetes mellitus: prevalence, impact, and treatment. Drugs 75(6) (2015) 577-587.
5. Casey DA. Depression in Older Adults: A Treatable Medical Condition. Primary Care 44(3) (2017) 499-510.
6. Yüzbaşıoğlu D, Avuloğlu Yılmaz E, Ünal F. Antidepresan ilaçlar ve genotoksisite. TÜBAV Bilim Dergisi 9(1) (2016) 17-28.
7. Gusmão R, Quintão S, McDaid D, et al. Antidepressant Utilization and Suicide in Europe: An Ecological Multi-National Study. PLoS One 8(6) (2013) e66455.
8. https://www.oecd-ilibrary.org/sites/43146d4b en/index.html?itemId=/content/component/43146d4b-en.

9. Lobo V, Patil A, Phatak A, Chandra N. Free radicals, antioxidants and functional foods: Impact on human health. Pharmacognosy Reviews 4(8) (2010) 118-126.
10. Otter J, McIntyre IM, Morhaime J, Cantrell L. A fluvoxamine-related fatality: Case report with postmortem concentrations. Forensic Science International 300 (2019) e31-e33.
11. Norizadeh Tazehkand M, Topaktas M. The in vitro genotoxic and cytotoxic effects of remeron on human peripheral blood lymphocytes. Drug and Chemical Toxicology. 38(3) (2015) 266-271.
12. Cuijpers P, Quero S, Dowrick C, Arroll B. Psychological Treatment of Depression in Primary Care: Recent Developments. Current Psychiatry Reports 21(12) (2019) 129.
13. Hashimoto K. Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication. Journal of Pharmacological Sciences 127(1) (2015) 6-9.
14. Rogrigo R. Oxidative stress and antioxidants: their role in human disease. Nova Science Publishers, pp. 2-18, New York, 2009.
15. Erel O. A new automated colorimetric method for measuring total oxidant status. Clinical Biochemistry 38 (2005) 1103–1111.
16. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clinical Biochemistry 37 (2004) 277– 285.
17. Istifli ES, Çelik R, Hüsunet MT, Çetinel N, Demirhan O, Ila HB. In vitro cytogenotoxic evaluation of sertraline. Interdisciplinary Toxicology 11(3) (2018) 181-188.
18. Abdel-Salam OME, Morsy SMY, Sleem AA. The effect of different antidepressant drugs on oxidative stress after lipopolysaccharide administration in mice. Experimental Clinical Science Journal 10 (2011) 290-302.